source
- Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trialDisc Medicine announced that its experimental therapy for a rare condition that makes sun exposure painful has completed a Phase 3 study. The trial reported success on every primary and secondary…
- Nouscom secures $135 million Series D to advance lead cancer vaccine into Phase 2Clinical-stage biotech Nouscom announced it has closed a $135 million Series D financing round that was oversubscribed. The capital will be used to move its lead cancer vaccine candidate into a Pha…